{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T10:24:45Z","timestamp":1777890285240,"version":"3.51.4"},"reference-count":31,"publisher":"Society of Nuclear Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.2967\/jnumed.119.232827","type":"journal-article","created":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T22:19:17Z","timestamp":1571437157000},"page":"649-654","source":"Crossref","is-referenced-by-count":46,"title":["Early <sup>18<\/sup>F-FDG PET\/CT Response Predicts Survival in Relapsed or Refractory Hodgkin Lymphoma Treated with Nivolumab"],"prefix":"10.2967","volume":"61","author":[{"given":"Aiping","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima-Zohra","family":"Mokrane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence H.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apasia","family":"Stamatoullas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marc","family":"Schiano de Colella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laetitia","family":"Vercellino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Casasnovas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrien","family":"Chauchet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Delmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuelle","family":"Nicolas-Virelizier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herv\u00e9","family":"Ghesqui\u00e8res","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Pierre","family":"Moles-Moreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9my","family":"Dulery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krimo","family":"Bouabdallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecile","family":"Borel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Touati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedicte","family":"Deau-Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Peyrade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain-David","family":"Seban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Manson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Armand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roch","family":"Houot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Dercle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1602","published-online":{"date-parts":[[2019,10,18]]},"reference":[{"key":"2021051712144687000_61.5.649.1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0004"},{"key":"2021051712144687000_61.5.649.2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/ejh.12770","article-title":"Pembrolizumab in classical Hodgkin\u2019s lymphoma","volume":"97","author":"Maly","year":"2016","journal-title":"Eur J Haematol."},{"key":"2021051712144687000_61.5.649.3","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol."},{"key":"2021051712144687000_61.5.649.4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-110960"},{"key":"2021051712144687000_61.5.649.5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00766"},{"key":"2021051712144687000_61.5.649.6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000215"},{"key":"2021051712144687000_61.5.649.7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejca.2019.04.006","article-title":"Long term benefit of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation","volume":"115","author":"Manson","year":"2019","journal-title":"Eur J Cancer."},{"key":"2021051712144687000_61.5.649.8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-841262"},{"key":"2021051712144687000_61.5.649.9","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1182\/blood.V128.22.1110.1110","article-title":"Checkmate 205 update with minimum 12-month follow up: a phase 2 study of nivolumab in patients with relapsed\/refractory classical Hodgkin lymphoma [abstract]","volume":"128","author":"Timmerman","year":"2016","journal-title":"Blood."},{"key":"2021051712144687000_61.5.649.10","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1182\/blood.V128.22.1107.1107","article-title":"Pembrolizumab in relapsed\/refractory classical Hodgkin lymphoma: primary end point analysis of the phase 2 keynote-087 study [abstract]","volume":"128","author":"Moskowitz","year":"2016","journal-title":"Blood."},{"key":"2021051712144687000_61.5.649.11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.193011"},{"key":"2021051712144687000_61.5.649.12","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ejca.2017.12.015","article-title":"Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma","volume":"91","author":"Dercle","year":"2018","journal-title":"Eur J Cancer."},{"key":"2021051712144687000_61.5.649.13","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.it.2019.03.003","article-title":"Immunotherapy in Hodgkin lymphoma: the road ahead","volume":"40","author":"Ansell","year":"2019","journal-title":"Trends Immunol."},{"key":"2021051712144687000_61.5.649.14","first-page":"CD010533","article-title":"Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma","volume":"1","author":"Sickinger","year":"2015","journal-title":"Cochrane Database Syst Rev."},{"key":"2021051712144687000_61.5.649.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510093"},{"key":"2021051712144687000_61.5.649.16","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S1470-2045(18)30784-8","article-title":"PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study","volume":"20","author":"Casasnovas","year":"2019","journal-title":"Lancet Oncol."},{"key":"2021051712144687000_61.5.649.17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-761346"},{"key":"2021051712144687000_61.5.649.18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1316"},{"key":"2021051712144687000_61.5.649.19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30167-X"},{"key":"2021051712144687000_61.5.649.20","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J Clin Oncol."},{"key":"2021051712144687000_61.5.649.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087"},{"key":"2021051712144687000_61.5.649.22","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2961-x"},{"key":"2021051712144687000_61.5.649.23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718528"},{"key":"2021051712144687000_61.5.649.24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"2021051712144687000_61.5.649.25","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s00259-018-4215-9","article-title":"Deauville score: the Phoenix rising from ashes","volume":"46","author":"Lopci","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2021051712144687000_61.5.649.26","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s00259-018-4171-4","article-title":"FDG PET\/CT for assessing tumour response to immunotherapy: report on the EANM symposium on immune modulation and recent review of the literature","volume":"46","author":"Aide","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2021051712144687000_61.5.649.27","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s00259-019-04310-x","article-title":"Unconventional immune-related phenomena observed using 18F-FDG PET\/CT in Hodgkin lymphoma treated with anti PD-1 monoclonal antibodies","volume":"46","author":"Dercle","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2021051712144687000_61.5.649.28","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med."},{"key":"2021051712144687000_61.5.649.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.03.006"},{"key":"2021051712144687000_61.5.649.30","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/ajh.25154","article-title":"Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers","volume":"93","author":"Rossi","year":"2018","journal-title":"Am J Hematol."},{"key":"2021051712144687000_61.5.649.31","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1093\/annonc\/mdx524","article-title":"The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin\u2019s lymphoma patients-the Polish Lymphoma Research Group (PLRG) Observational Study","volume":"28","author":"Zaucha","year":"2017","journal-title":"Ann Oncol."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.119.232827","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T20:48:10Z","timestamp":1621284490000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.119.232827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,18]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5,1]]},"published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10.2967\/jnumed.119.232827"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.119.232827","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,18]]}}}